Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

Overview of attention for article published in The Journal of Headache and Pain, June 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 33 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 12,945 followers.

RCTs include carefully selected populations, and real-world data is necessary to generate evidence from clinical practice. In this real-world long-term study of patients with chronic #migraine, #erenumab was effective and well-tolerated: https://t.co/MkE4z

12 Jun 2022

Reply Repost Favourite

RT @hmru_cph: Real-world data of #erenumab in 300 patients over 52 weeks! Among patients with chronic #migraine and previous failure of med…

04 Jun 2022

Reply Repost Favourite

RT @hmru_cph: Real-world data of #erenumab in 300 patients over 52 weeks! Among patients with chronic #migraine and previous failure of med…

03 Jun 2022

Reply Repost Favourite

RT @hmru_cph: Real-world data of #erenumab in 300 patients over 52 weeks! Among patients with chronic #migraine and previous failure of med…

03 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.